Xact Kapitalforvaltning AB trimmed its position in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 7.0% during the 3rd quarter, HoldingsChannel reports. The fund owned 7,725 shares of the medical equipment provider’s stock after selling 578 shares during the period. Xact Kapitalforvaltning AB’s holdings in ABIOMED were worth $3,474,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently modified their holdings of ABMD. MERIAN GLOBAL INVESTORS UK Ltd raised its holdings in shares of ABIOMED by 1,030.0% during the 3rd quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 638,856 shares of the medical equipment provider’s stock worth $287,325,000 after acquiring an additional 582,318 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of ABIOMED by 35.0% during the 2nd quarter. Renaissance Technologies LLC now owns 1,551,423 shares of the medical equipment provider’s stock worth $634,610,000 after acquiring an additional 401,800 shares in the last quarter. FMR LLC raised its holdings in shares of ABIOMED by 34.2% during the 2nd quarter. FMR LLC now owns 691,818 shares of the medical equipment provider’s stock worth $282,988,000 after acquiring an additional 176,394 shares in the last quarter. Carillon Tower Advisers Inc. raised its holdings in shares of ABIOMED by 77.0% during the 2nd quarter. Carillon Tower Advisers Inc. now owns 400,348 shares of the medical equipment provider’s stock worth $163,762,000 after acquiring an additional 174,198 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. purchased a new stake in shares of ABIOMED during the 2nd quarter worth approximately $58,965,000. 86.86% of the stock is currently owned by institutional investors and hedge funds.
In related news, VP Michael G. Howley sold 10,000 shares of the stock in a transaction on Tuesday, September 25th. The stock was sold at an average price of $432.50, for a total transaction of $4,325,000.00. Following the sale, the vice president now owns 48,954 shares in the company, valued at approximately $21,172,605. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Andrew J. Greenfield sold 4,440 shares of the stock in a transaction on Wednesday, August 29th. The shares were sold at an average price of $395.00, for a total value of $1,753,800.00. The disclosure for this sale can be found here. Corporate insiders own 3.50% of the company’s stock.
NASDAQ:ABMD opened at $320.03 on Tuesday. ABIOMED, Inc. has a fifty-two week low of $177.40 and a fifty-two week high of $459.75. The firm has a market cap of $14.83 billion, a P/E ratio of 130.62, a P/E/G ratio of 3.53 and a beta of 0.03.
ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.
Recommended Story: What are the most popular ETFs
Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.